ZL006-05 is an orally active, brain-penetrant nNOS–PSD-95 and α2-containing GABA A dual-target inhibitor. ZL006-05 blocks the nNOS-PSD-95 protein-protein interaction and selectively potentiatesα2-containing GABA A receptors. ZL006-05 attenuates central sensitization and strengthens inhibitory GABAergic synaptic transmission. ZL006-05 can be used for the study of neuropathic pain, cancer pain, chemotherapy-induced peripheral neuropathic pain, ischemic stroke, poststroke depression and anxiety.
Products | Products > Disease Areas > Anxiety or Fear-Related Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Depression | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > iGluR | Products > Signaling Pathways > GABA Receptor | Products > Signaling Pathways > NO Synthase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.